Undervalued Stocks
RIGL is currently part of our Undervalued Stocks screen, meaning it meets strict valuation and quality criteria
RIGEL PHARMACEUTICALS INC (RIGL) Stock Price & Overview
NASDAQ:RIGL • US7665597024
Current stock price
27.53 USD
+0.03 (+0.11%)
At close:
27.53 USD
0 (0%)
After Hours:
The current stock price of RIGL is 27.53 USD. Today RIGL is up by 0.11%. In the past month the price decreased by -6.74%. In the past year, price increased by 59.69%.
RIGL Key Statistics
52-Week Range15.5 - 52.24
Current RIGL stock price positioned within its 52-week range.
1-Month Range24.95 - 29.67
Current RIGL stock price positioned within its 1-month range.
- Market Cap
- 508.479M
- P/E
- 4.22
- Fwd P/E
- 6.65
- EPS (TTM)
- 6.52
- Dividend Yield
- N/A
RIGL Stock Performance
Today
+0.11%
1 Week
+4.40%
1 Month
-6.74%
3 Months
-34.19%
Longer-term
6 Months -3.54%
1 Year +59.69%
2 Years +162.19%
3 Years +143.63%
5 Years -25.99%
10 Years -2.72%
RIGL Stock Chart
RIGL Stock Screens
RIGL currently appears in the following ChartMill screener lists.
High Free Cash Flow Stocks
RIGL is currently part of our High Free Cash Flow Stocks screen, indicating it generates strong cash flows relative to its price.
Low P/E Stocks
RIGL is currently part of our Low P/E Stocks screen, indicating it cheap while it also meets financial health criteria.
Value Stocks with Strong Balance Sheets
RIGL is currently part of our value stocks with Strong Balance Sheets screen, indicating it cheap while meeting strict financial health and debt criteria.
Fastest Growing Stocks
RIGL is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
Revenue Growth Leaders
RIGL is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
RIGL Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to RIGL. When comparing the yearly performance of all stocks, RIGL turns out to be only a medium performer in the overall market: it outperformed 63.28% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
RIGL Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to RIGL. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RIGL Earnings
On March 3, 2026 RIGL reported an EPS of 1.15 and a revenue of 69.80M. The company missed EPS expectations (-9.57% surprise) and missed revenue expectations (-0.39% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateMar 3, 2026
PeriodQ4 / 2025
EPS Reported$1.15
Revenue Reported69.802M
EPS Surprise -9.57%
Revenue Surprise -0.39%
RIGL Forecast & Estimates
12 analysts have analysed RIGL and the average price target is 52.22 USD. This implies a price increase of 89.7% is expected in the next year compared to the current price of 27.53.
For the next year, analysts expect an EPS growth of -36.48% and a revenue growth -3.09% for RIGL
Analysts
Analysts80
Price Target52.22 (89.68%)
EPS Next Y-36.48%
Revenue Next Year-3.09%
RIGL Groups
Sector & Classification
RIGL Financial Highlights
Over the last trailing twelve months RIGL reported a non-GAAP Earnings per Share(EPS) of 6.52. The EPS increased by 593.62% compared to the year before.
Income Statements
Revenue(TTM)294.28M
Net Income(TTM)367.02M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 124.72% | ||
| ROA | 71.46% | ||
| ROE | 93.75% | ||
| Debt/Equity | 0.06 |
Chartmill High Growth Momentum
EPS Q2Q%43.75%
Sales Q2Q%21.19%
EPS 1Y (TTM)593.62%
Revenue 1Y (TTM)64.15%
RIGL Ownership
Ownership
Inst Owners91.09%
Shares18.47M
Float17.91M
Ins Owners3.09%
Short Float %20.83%
Short Ratio10.82
RIGL Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RIGL
Company Profile
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 172 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Company Info
IPO: 2000-11-29
RIGEL PHARMACEUTICALS INC
611 Gateway Boulevard, Suite 900
South San Francisco CALIFORNIA 94080 US
CEO: Raul R. Rodriguez
Employees: 172
Phone: 13025814070
RIGEL PHARMACEUTICALS INC / RIGL FAQ
What does RIGEL PHARMACEUTICALS INC do?
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 172 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. The company is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
What is the current price of RIGL stock?
The current stock price of RIGL is 27.53 USD. The price increased by 0.11% in the last trading session.
Does RIGL stock pay dividends?
RIGL does not pay a dividend.
What is the ChartMill technical and fundamental rating of RIGL stock?
RIGL has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Which stock exchange lists RIGL stock?
RIGL stock is listed on the Nasdaq exchange.
Would investing in RIGEL PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on RIGL.